Albany Molecular Research, Inc. (AMRI) Quote

AMRI bullish https://stocknews.com/news/amri-headlines-that-the-company-is-in-acquisition-talks-with-private/

Buyout ?

AMRI bullish 18.28









normal chart




log chart

time to buy!!!

nice call

luv it, back into the 20's..ho rah!

very interesting

congrats, to all the Oct buyers!!! Divy's r a coming

$AMRI recent news/filings

bullish 20.07
moving aveerage support

## source: finance.yahoo.com

Tue, 24 Nov 2015 16:23:00 GMT ~ Smart Money Is Losing Confidence In Community Trust Bancorp, Inc. (CTBI)


read full: http://www.insidermonkey.com/blog/smart-money-is-losing-confidence-in-community-trust-bancorp-inc-ctbi-387804/
*********************************************************

Tue, 17 Nov 2015 18:04:27 GMT ~ ALBANY MOLECULAR RESEARCH INC Financials


read full: http://finance.yahoo.com/q/is?s=amri
*********************************************************

Fri, 13 Nov 2015 13:00:00 GMT ~ AMRI CEO to Present at Jefferies Autumn 2015 Global Healthcare Conference London

[PR Newswire] - ALBANY, N.Y., Nov. 13, 2015 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Jefferies ...

read full: http://finance.yahoo.com/news/amri-ceo-present-jefferies-autumn-130000443.html
*********************************************************

Mon, 09 Nov 2015 20:19:57 GMT ~ ALBANY MOLECULAR RESEARCH INC Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/151109/amri10-q.html
*********************************************************

Fri, 06 Nov 2015 02:21:38 GMT ~ Edited Transcript of AMRI earnings conference call or presentation 5-Nov-15 1:30pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-amri-earnings-conference-022138910.html
*********************************************************

$AMRI charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$AMRI company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AMRI/company-info
Ticker: $AMRI
OTC Market Place: Not Available
CIK code: 0001065087
Company name: Albany Molecular Research, Inc.
Incorporated In: DE, USA

$AMRI share structure

## source: otcmarkets.com

Market Value: $712,520,644 a/o Dec 04, 2015
Shares Outstanding: 35,501,776 a/o Oct 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

$AMRI extra dd links

Company name: Albany Molecular Research, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AMRI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AMRI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AMRI+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/news - http://finance.yahoo.com/q/h?s=AMRI+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AMRI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AMRI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AMRI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Albany+Molecular+Research%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Albany+Molecular+Research%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Albany+Molecular+Research%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AMRI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001065087&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AMRI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AMRI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AMRI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AMRI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AMRI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AMRI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AMRI+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AMRI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AMRI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AMRI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AMRI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AMRI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AMRI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AMRI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AMRI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AMRI



$AMRI DD Notes ~ http://www.ddnotesmaker.com/AMRI

luv this little baby

to the moon

, this one is a keeper

Look for a possible breakout about to happen on the chart

not bad , for the last 2 yrs

might level off for now!

Albany Molecular Research's CEO Discusses Q1 2013 Results - Earnings Call Transcript

http://seekingalpha.com/article/1409941-albany-molecular-research-s-ceo-discusses-q1-2013-results-earnings-call-transcript?source=yahoo

8:06AM Albany Molecular beats on top and bottom line; issues upside guidance (AMRI) 5.66 : Reports Q4 (Dec) earnings of $0.17 per share, $0.08 better than the Capital IQ single analyst estimate of $0.09; revenues rose 44.2% year/year to $67.2 mln vs the $56.5 mln single analyst est.

Total contract revenue for the fourth quarter of 2012 was $59.1 million, an increase of 50% compared to total contract revenue of $39.4 million reported in the fourth quarter of 2011. Contract margin improved to 18% from (2%) in the prior-year period.
Co issues upside guidance for FY13, sees EPS of $0.34-0.52 vs. $0.24 Capital IQ single analyst est. Sees contract revenue growth between 8% and 12%; continued improvement in contract margin to between 14% and 16%.
"We are pleased to report fourth quarter and full year results for 2012, which reflect operating improvements largely driven by the record performance in our Large Scale Manufacturing business. In addition, a number of actions taken in prior periods are demonstrating a positive impact on our bottom line."

AMRI to Announce Fourth Quarter Results
Press Release: AMRI – Tue, Jan 15, 2013 8:00 AM EST

ALBANY, N.Y., Jan. 15, 2013 /PRNewswire/ -- AMRI (AMRI) today announced it will issue fourth quarter and full year financial results before the opening of the market on Tuesday, February 12, 2013. Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. ET.
(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )
The conference call can be accessed by dialing 888-438-5535 (domestic calls) or 719-325-2455 (international calls) at 9:50 a.m. ET and entering passcode 2539488. The webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.

Form 8-K for ALBANY MOLECULAR RESEARCH INC 30-Nov-2012

Costs Associated with Exit or Disposal Activities, Regulation FD Di

Item 2.05 Costs Associated with Exit or Disposal Activities

On November 29, 2012, Albany Molecular Research, Inc. (the "Company") approved a restructuring plan related to its operations in Bothell, Washington.

As a result of shifting market preferences related to integrated drug discovery activities, the Company will further optimize its location footprint by closing its Bothell, WA site. The site's biology capabilities will transition to the Company's fully integrated discovery location in Singapore and certain analytical capabilities will consolidate into the Company's analytical quality group in Albany, N.Y.

In connection with the restructuring plan, the Company expects to cease all operations at its Bothell facility effective March 31, 2013. The Bothell facility currently has 24 employees.

As a result of the restructuring, the Company will be terminating the lease of its Bothell facility which will result in a reduction in annual operating expenses related to this facility. The Company expects that these cost reduction initiatives will result in annual savings of approximately $2.0 million which will begin to be recognized in the second quarter of 2013.

In connection with these actions, the Company expects to incur pre-tax charges of approximately $11 million which includes a $4.5 - $5.0 million non-cash fixed asset impairment. Cash charges will consist of $4.0 - $4.5 million for estimated lease obligations to be paid ratably over 24 months commencing in Q2 2013 and approximately $2.0 - $2.5 million for employee and other related costs to be paid during the first half of 2013. The Company expects the majority of these charges to be recorded in the fourth quarter of 2012 and in the first quarter of 2013.



Item 7.01 Regulation FD Disclosure

On November 30, 2012, the Company issued a press release announcing its restructuring plan. A copy of the press release is attached hereto and furnished herewith as Exhibit 99.1.

7:33AM Albany Molecular appoints Michael Nolan VP, CFO and Treasurer (AMRI) 3.38 : Co announced the appointment of Michael Nolan as Vice President, Chief Financial Officer and Treasurer of AMRI, succeeding Mark Frost, effective September 17, 2012. Mr. Nolan was most recently Vice President, Finance, Financial Planning and Analysis at the Delaware North Companies.

AMRI Further Expands Discovery Capabilities in India
Two Strategic Hires Bring Additional Flexibility to Global Drug Discovery Operations
PR NewswirePress Release: AMRI – Tue, Jun 19, 2012 8:00 AM EDT

ALBANY, N.Y., June 19, 2012 /PRNewswire/ -- As part of a long-term strategic plan to further AMRI's discovery capabilities in India, AMRI (AMRI), a leading global contract research and manufacturing organization, announced the hiring of two experts in medicinal and computational chemistry at its research center located in Hyderabad, India (HRC). Simultaneously, the company announced the completion of the relocation of custom library synthesis resources and capabilities to HRC from the Company's Budapest, Hungary operations. The new hires and relocation of resources provide additional flexibility to enhance productivity and client service for AMRI's global drug discovery operations, which draw upon a broad spectrum of service capabilities from multiple sites.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

Srinivas Nanduri, Ph.D., was hired as Director of Medicinal Chemistry in India, reporting to Subramanyam Maddala, President of India Operations. In addition, Suneel Kumar Bommisetty, Ph.D., was hired as Senior Research Associate of Computational Chemistry, reporting to Dr. Nanduri. These newly created positions will further strengthen AMRI's capabilities in problem-solving medicinal chemistry and complement its current strength in custom synthesis at HRC.

"Dr. Nanduri and Dr. Bommisetty bring a high level of medicinal chemistry expertise, a strong track record of industry experience and additional drug discovery project management experience to the Hyderabad site," Mr. Maddala said. "AMRI is committed to providing best-of-class services to our customers, and servicing the entire value chain of contract research services. These additions enhance our capabilities to move towards that target."

In his most recent role as Research Director at Aurigene, Dr. Nanduri was responsible for the execution and overall supervision of multiple integrated drug discovery projects – from hit generation through lead optimization. Prior to that, he was a Chief Scientific Manager at Biocon-BMS Research Centre, where he led projects in the therapeutic areas of oncology, obesity and central nervous system disorders. Dr. Nanduri also had worked at Dr. Reddy's, where he led multiple medicinal chemistry projects in oncology and metabolic disorders, as well as a number of natural products projects in the area of anti-cancer therapy. Dr. Nanduri earned a Ph.D. in Organic Chemistry from Sri Sathya Sai Institute in Andhra Pradesh, India.

Dr. Bommisetty joins AMRI from GVK Biosciences Pvt. Ltd. and brings more than eight years of computational chemistry experience to HRC. He began his career as a Research Associate in 2004 while he obtained his Ph.D. in Computational Chemistry from JNTU. He played a dual role in GVK as a Scientific Associate and also as a senior faculty in GVK Bio campus, leading theory classes and lab sessions on Molecular Modeling, Homology Modeling, Structure-based Drug Design and Analogue-based Drug Design.

Bruce J. Sargent, Ph.D., Senior Vice President of Drug Discovery, commented, "At AMRI we continue to expand our world-class team of scientists to ensure our customers have access to the most experienced and technically adept experts to address their increasingly complex challenges. With the addition of Dr. Nanduri and Dr. Bommisetty, AMRI expands its global medicinal and computational chemistry capabilities in India, complementing the existing capabilities in the U.S. and Singapore. Strengthening our HRC capabilities is an essential element of our SMARTSOURCING™ strategy, which brings together the right mix of AMRI global services, capabilities and translational expertise, while maintaining the same high standards for performance, quality and productivity."

8:04AM Albany Molecular misses by $0.03, beats on revs; guides FY12 EPS in-line (AMRI) 3.01 : Reports Q1 (Mar) earnings of $0.02 per share, $0.03 worse than the Capital IQ Consensus Estimate of $0.05; revenues fell 5.6% year/year to $53.7 mln vs the $52.12 mln consensus. Co issues in-line guidance for FY12, sees EPS of $0.06-0.12 vs. $0.09 Capital IQ Consensus Estimate. "In the second quarter, we expect contract revenue to range from $40 million to $43 million. For the full year 2012, we continue to expect contract revenue to range from $176 million to $186 million, an increase of up to 10% versus 2011... We expect second quarter royalties of $8 to $9 million and full year 2012 royalties of $32 to $36 million. We are raising our contract gross margin estimate for the year to range from 6-10% but anticipate variability between the quarters related to mix."

AMRI short summary of recent history:
InPlay: Albany Molecular announces development and manufacturing deal with Biota Holdings - Yahoo, 1:17:00 AM

AMRI Announces Development and Manufacturing Deal with Biota Holdings Limited - PR Newswire, 1:00:00 AM


ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materi - Yahoo, 4/12/2012 9:47:00 AM



ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and - Yahoo, 4/5/2012 9:30:00 AM


InPlay: Albany Molecular signs exclusive option to license its tubulin inhibitor program for cancer - Yahoo, 4/3/2012 1:03:00 AM

AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer - PR Newswire, 4/3/2012 1:00:00 AM

AMRI CFO to Present at 11th Annual Needham Healthcare Conference - PR Newswire, 3/28/2012 1:00:00 AM





AMRI Hires Senior Manager to Oversee Facilities at Burlington Aseptic Fill Operations - PR Newswire, 3/27/2012 1:00:00 AM

ALBANY MOLECULAR RESEARCH INC Financials - Yahoo, 3/22/2012 6:04:00 AM




UPDATE 1-Albany Molecular to close Hungary unit, cut 100 jobs - Reuters, 3/21/2012 10:27:00 AM

ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities - Yahoo, 3/21/2012 10:02:00 AM

ALBANY MOLECULAR RESEARCH INC Files SEC form 10-K, Annual Report - Yahoo, 3/15/2012 9:20:00 AM

0
AMRI Expands Quality Control Leadership to Support Future Growth - PR Newswire, 2/29/2012



5 Biotech Stocks Undervalued By EPS Trends - Seeking Alpha, 2/12/2012 7:21:00 PM

New Star Analyst Rankings for Albany Molecular Research, Inc. - , 2/8/2012 1:31:00 AM



DIARY-U.S. MEETINGS/WEEK AHEAD - Reuters, 2/8/2012 12:25:00 AM

ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - Yahoo, 2/7/2012 9:03:00 AM
-



AMRI reports net loss of $32M in 2011 - Business Journals, 2/7/2012 4:08:00 AM

AMRI Announces Fourth Quarter and Full Year 2011 Results - PR Newswire, 2/7/2012

8:17AM Albany Molecular announces development and manufacturing deal with Biota Holdings (AMRI) 2.80 : Co was selected by Biota Holdings, an anti-infective drug development company based in Australia, to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. AMRI will provide these services to support a New Drug Application for laninamivir to the FDA. AMRI's role will initially involve the development and manufacture of the active pharmaceutical ingredient for use in clinical trials. In the future there is the potential for AMRI to be selected as the commercial manufacturer of the product.

8:03AM Albany Molecular signs exclusive option to license its tubulin inhibitor program for cancer (AMRI) 2.70 : Co announces it has signed an exclusive option to enter a license agreement with Bessor Pharma for the development of ALB 109564a, co's novel tubulin inhibitor compound in late Phase I testing for the treatment of cancer. Co will receive an undisclosed option fee and reimbursement for certain costs associated with the intellectual property related to ALB 109564(a). The option period is approximately eight months, during which time Bessor Pharma will conduct further due diligence, engage in the required fund raising and coordinate with AMRI a technology transfer and advanced development plan. Upon exercising the option, Bessor Pharma will receive an exclusive license to the ALB 109564(a) intellectual property, and be solely responsible for all related research and development and patent costs. AMRI will receive royalties on sales of any ALB 109564(a)-related drug that is commercialized, in addition to the potential to earn additional revenue as the manufacturer of the drug itself. In the event that the option is not exercised, all rights to ALB 109564(a) will revert to AMRI.

~ $AMRI ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $AMRI ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=AMRI&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=AMRI&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/AMRI?
~ OTC Markets: http://www.otcmarkets.com/stock/AMRI/company-info
~ Google Finance: http://www.google.com/finance?q=AMRI
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=AMRI#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=AMRI+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=AMRI
Finviz: http://finviz.com/quote.ashx?t=AMRI
~ BusyStock: http://busystock.com/i.php?s=AMRI&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=AMRI&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=AMRI
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=AMRI
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=AMRI
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=AMRI
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=AMRI
~ MarketWatch: http://www.marketwatch.com/investing/stock/AMRI/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=AMRI
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=AMRI
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=AMRI&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=AMRI&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=AMRI&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

8:08AM Albany Molecular to review of its Hungary operation; co to evaluate options to enhance customer service and improve efficiency (AMRI) 2.89 : Co announced that as part of its ongoing global operations review to improve efficiency and customer service, it is considering a restructuring of its European operations focused on a reduction of the workforce in the second quarter of 2012 and potential further actions at its Budapest, Hungary operation.

nice volume increase to end the week. wonder what that's all about.

AMRI Presents Final Phase I Clinical Studies Results of Obesity Compound at the 29th Annual Scientific Meeting of the Obesity Society

Press Release Source: Albany Molecular Research, Inc. On Monday October 3, 2011, 8:00 am EDT

ALBANY, N.Y.--(BUSINESS WIRE)-- AMRI (NASDAQ:AMRI - News) announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla. Nicholas Moore, Ph.D., director of development and pharmacology at AMRI, reported results from a second Phase I study showing cerebrospinal fluid (CSF) drug levels were achieved with a single 400 mg oral dose of ALB-127158(a). The finding is significant in that it indicates brain/CNS penetration and suggests the compound will reach the drug target receptor in the brain.

Dr. Moore also reiterated previously reported results from a placebo-controlled study which evaluated the safety, tolerability, and efficacy of ALB-127158(a). The study, comprising the single ascending dose (SAD) and 14-day multiple ascending dose (MAD) arms, included standard safety assessments, ECG monitoring, and PK measurements. ALB-127158(a) was well tolerated in both the SAD and the MAD. Reported events were mild and showed little dose relationship. One of the most common events reported in both the SAD and the MAD was loss of appetite. Reductions in “hunger,” “desire to eat,” and test meal consumption were observed. The study met both its primary and secondary objectives, demonstrating safety and tolerability.

Analysis of the CSF and other data suggested a higher than predicted dose would be required for chronic treatment. Therefore, AMRI has decided not to progress ALB-127158(a) further.

“Although we have decided not to progress ALB-127158(a) toward Phase II clinical studies, we have multiple follow-on compounds that we believe may show better potential for partnering and clinical development,” said Bruce Sargent, Ph.D., senior vice president of drug discovery.

2. Albany Molecular Research Inc. (AMRI): Biotechnology Industry. Market cap of $103.63M. Net institutional shares sold over the current quarter at 2.7M, which is 12.15% of the company's 22.22M share float.

http://seekingalpha.com/article/290509-10-biotech-stocks-being-dumped-by-big-money-managers?source=yahoo

http://www.insidercow.com/history/company.jsp?company=AMRI&B1=Search!

http://quotes.barrons.com/AMRI/ownership

AMRI awarded NIH contract worth as much as $43M
The Business Review - by Barbara Pinckney
Date: Friday, August 19, 2011, 11:07am EDT

AMRI has been awarded an NIH grant worth as much as $43 million.
Richard A. D'Errico | The Business Review

AMRI has been awarded an NIH grant worth as much as $43 million.

Albany Molecular Research Inc. has been awarded a National Institutes of Health contract that could be worth up to $43 million over five years.

The Albany, N.Y.-based company will provide chemistry and other drug discovery technologies to support efforts by the National Institute of Neurological Disorders and Stroke (NINDS), an arm of the NIH, to develop pre-clincal drug candidates to treat diseases of the central nervous system.

AMRI has been collaborating with NINDS since 2005 on novel treatments for spinal muscular atrophy, a degenerative neuromuscular disease. The company now will provide its chemistry services to neuroscientists throughout the country with the goal of developing pre-clinical drug candidates suitable for advanced development and ultimately clinical trials in humans.

The company will receive initial funding of up to $10 million for the first phase of the project, expected to begin this month, with the objective of delivering at least one Phase I clinical trial candidate. It could receive up to $43 million based on the number of approved projects and availability of funds over five years.

Thomas D’Ambra, chairman, president and CEO of AMRI, said the company was chosen after a “highly competitive, rigorous application process.”

“We are pleased to support NIH/NINDS’ efforts and provide our discovery resources to the neuroscience research community and to patients who suffer from devastating neurological and degenerative diseases, such as macular degeneration and Alzheimer’s disease,” added Dr. D’Ambra. ...

Albany Molecular beats by $0.01, beats on revs (AMRI) 4.36 : Reports Q2 (Jun) loss of $0.02 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.03); revenues rose 8.9% year/year to $53.9 mln vs the $52.4 mln consensus. "In the third quarter, we expect contract revenue to range from $43 million to $47 million, an increase of up to 10% versus 2010. For the full year 2011, we continue to expect contract revenue to range from $179 million to $187 million, an increase of up to 15% versus 2010."

good looking chart -- will pounce on this if we get a pullback to the 50DMA around $4.8; if I'm lucky tomorrow's jobs report could do just that

Financials good... uptrend coming IMO.

http://biz.yahoo.com/e/071109/amri10-q.html

Nearing entry point IMO... maybe by Tuesday.

Big drop today........

AMRI Announces Third Quarter Results; Continues Double-Digit Growth in Contract Revenue and EPS

Albany, NY (November 6, 2007) — AMRI (NASDAQ: AMRI) today announced results for the third quarter ended September 30, 2007. For the quarter, the company reported growth in total contract revenue and net income. Growth was driven by continued strong performance in the company’s Development/Small Scale business component.

Highlights for the quarter include:

* An increase in total revenue, including 10% growth in contract revenue
* Double-digit year-over-year contract revenue growth in Development/Small Scale business segments
* Operating income increased 173%, from $0.8 million in Q3 2006 to $2.1 million in Q3 2007
* Net income of $2.0 million, a 41% increase year-over-year
* Year-over-year improvement in contract services gross margin
* The opening of a new R&D facility in Hyderabad, India
* A four-year research collaboration with the Cystic Fibrosis Foundation worth up to $23.7 million, aimed at identifying novel treatments that address the core defect in cystic fibrosis
* The hiring of Steve Jennings, a 30-year veteran of both the pharmaceutical and medical device industries, to lead AMRI’s global sales and business development efforts.

Third Quarter Results

Total revenue for the third quarter of 2007 was $47.6 million, an increase of 8% compared to total revenue of $44.2 million in the third quarter of 2006.

Total contract revenue in the third quarter of 2007 was $41.6 million, an increase of 10% compared to total contract revenue of $37.9 million in the third quarter of 2006. Total contract revenue encompasses revenue from AMRI’s Discovery Services, Development/Small Scale Manufacturing, and Large Scale Manufacturing business components.

* Development/Small Scale Manufacturing - contract revenue for the third quarter was $13.1 million, an increase of 37% compared to $9.6 million in the third quarter of 2006. The increase results from continued strong demand for pharmaceutical development services.
* Discovery Services - contract revenue for the third quarter of 2007 was $10.5 million, an increase of 5% from $10 million in the third quarter of 2006.
* Large Scale Manufacturing - contract revenue for the third quarter of 2007 was $17.9 million, a decrease of 2% compared to $18.2 million in the third quarter of 2006.

Recurring royalties from Allegra® in the third quarter of 2007 were $6.0 million, a decrease of 6% compared to recurring royalties of $6.3 million in 2006. AMRI earns royalties from worldwide sales of the non-sedating antihistamine Allegra® (Telfast® outside the United States), as well as the authorized generic, for patents relating to the active ingredient in Allegra.

Net income in the third quarter of 2007 was $2.0 million, or $0.06 per diluted share, compared to net income of $1.4 million, or $0.04 per diluted share, in the third quarter of 2006.

Year-to-Date

Total revenue for the first nine-months of 2007 was $145.3 million, an increase of 9% compared to total revenue of $133.2 million during the same period in 2006.

Total contract and milestone revenue for the first nine-months of 2007 was $124.3 million, an increase of 11% compared to total contract and milestone revenue of $112.5 million during the comparable period in 2006.

Total contract revenue for the first nine-months of 2007 was $122.7 million, an increase of 9% compared to total contract revenue of $112.5 million in 2006.

* Development/Small Scale Manufacturing - contract revenue for the nine-month period ended September 30, 2007 was $34.0 million, an increase of 27% from $26.8 million in 2006.
* Discovery Services - contract revenue was $30.1 million, an increase of 10% from $27.3 million in 2006.
* Large Scale Manufacturing - contract revenue was $58.6 million, an increase of 1% compared to $58.2 million in the nine-month period ended September 30, 2006.

Milestone revenue for the first nine-months of 2007 was $1.6 million. Milestone revenue includes $1.5 million recorded in the second quarter of 2007, which resulted from the company’s 2005 licensing agreement with Bristol-Myers Squibb.

Recurring royalties from Allegra® for the first nine-months of 2007 were $21.0 million, an increase of 1% compared to royalty revenue of $20.7 million in 2006.

Net income under U.S. generally accepted accounting principles (U.S. GAAP) for the nine-month period ended September 30, 2007 was $9.8 million, or $0.30 per diluted share, compared to net income of $2.9 million, or $0.09 per diluted share, for the comparable period in 2006. Excluding Large Scale Manufacturing restructuring charges of $185,000 (net of taxes) recorded in the first and second quarters of 2007, net income for the nine months ended September 30, 2007 on an adjusted basis was $10.0 million, or $0.31 per diluted share. Excluding the charge recorded in the second quarter of 2006 to reduce the carrying value of the former Mount Prospect Research Center, net income for the nine-months ended September 30, 2006 on an adjusted basis was $5.2 million, or $0.16 per diluted share. For a reconciliation of net income and earnings per diluted share as reported to adjusted net income and earnings per diluted share, please see Table 1 at the end of this press release.

AMRI Chairman, President and CEO Thomas E. D'Ambra said, “Contract revenue for the third quarter grew 10% from last year and was on the high end of our contract revenue projections. Noteworthy, during the third quarter we saw continued revenue growth in our Discovery Services and Development/Small Scale business components. Our development/small scale component in particular remained very strong, with a 37% year-over-year quarterly increase and a 27% year-to-date increase. On the Discovery Services side, several natural products collaborations helped drive revenue growth, particularly at our U.S.-based operations. As we ramp up our international operations and begin to fully realize the benefits of our flexible cost model, we have high expectations for continued long-term growth in worldwide Discovery Services. In Large Scale Manufacturing we continue to remain on track in our overall efforts to improve the product mix and, more importantly, our margins. Our recently announced purchase of large scale manufacturing facilities in India (now referred to as AMRI India) is expected to be accretive to earnings in 2008.”

D'Ambra continued, “we continue to be bullish about the near- and long-term potential of our natural products collections. Within the past year we have initiated natural products-based research collaborations with four different customers. Many of these collaborations offer AMRI the opportunity to receive upfront payments, funded research and downstream revenue potential. AMRI’s investment in these resources and complementary technologies is beginning to deliver and impact our bottom line.”

Liquidity and Capital Resources

At September 30, 2007, AMRI had cash, cash equivalents and investments of $105.9 million, compared to $110.9 million at June 30, 2007. The decrease of $5 million in cash, cash equivalents and investments in the third quarter of 2007 was due primarily to purchases of property, plant and equipment of $4.6 million, and principal payments on the company's outstanding debt of $1.0 million. These items were partially offset by cash flow from operations of $0.6 million. Cash flow from operations increased by $0.6 million in the third quarter of 2007 as compared to the third quarter of 2006. Total debt at September 30, 2007 was $15.1 million, compared to $18.5 million at December 31, 2006. Cash, cash equivalents and investments, net of debt, were $90.8 million at September 30, 2007. Total common shares outstanding, net of treasury shares, at September 30, 2007 were 32,945,555.

Contract & Milestone Revenue Guidance

AMRI Chief Financial Officer Mark T. Frost provided contract revenue guidance for the fourth quarter, as well as contract and milestone revenue guidance for the full year 2007. “In the fourth quarter, we expect contract revenue to range from $43 million to $45 million, an increase of up to 11% from the fourth quarter of 2006,” he said. “For the full year 2007, we estimate contract and milestone revenue to range of $167 to $169 million, an increase of up to 11% from 2006.”

Third Quarter Conference Call

The company will hold a conference call at 10:00 a.m. Eastern Time on November 6, 2007 to discuss its quarterly results, business highlights and prospects. During the conference call, the company may discuss information not previously disclosed to the public. Individuals interested in listening to the conference call should dial 866-550-6338 (for domestic calls) or 347-284-6930 (for international calls) at 9:45 a.m. and use passcode 4648533. Replays of the call will be available for seven days following the call beginning at 12:00 p.m. on November 6, 2007. To access the replay by telephone, please call 888-203-1112 (for domestic calls) or 719-457-0820 (for international calls) and use access code 4648533. In addition, replays of the call will be available for twelve months on the company's website at www.amriglobal.com/investor/investcc.html.

Big drops... big recovery on this one.... double digit third quarter earnings. Look for bottom.